NT-proBNP levels in systemic sclerosis: Association with clinical and laboratory abnormalities

Clinical Biochemistry

Volumn 43, Issue 9, 2010, Pages 745-749

  Oravec, Rejane Maria ^a   Bredemeier, Markus ^b   Laurino, Claudia Cilene ^b   Pinotti, Antônio Fernando Furlan ^b   Rohde, Luis Eduardo Paim ^b   Brenol, João Carlos Tavares ^b   Xavier, Ricardo Machado ^b  

^a Laboratorio Weinmann   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Doppler echocardiography; Hypertension arterial pulmonary; Pro brain natriuretic peptide (1 76); Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CENTROMERE ANTIBODY;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIASTOLIC DYSFUNCTION; DYSPNEA; FEMALE; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 77952951014     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.03.011     Document Type: Article

References (30)

1. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15(2):202-205.
2. Trad S., Amoura Z., Beigelman C., Haroche J., Costedoat N., Boutin lT. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006, 54(1):184-191.
3. Allanore Y., Wahbi K., Borderie D., Weber S., Kahan A., Meune C. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?. Ann Rheum Dis 2009, 68:1885-1889.
4. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537.
5. Mukerjee D., St George D., Knight C., Davar J., Wells A.U., Du Bois R.M., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004, 43(4):461-466.
6. Nagaya N., Nishikimi T., Okano Y., Uematsu M., Satoh T., Kyotani S., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31(1):202-208.
7. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102(8):865-870.
8. Allanore Y., Borderie D., Meune C., Cabanes L., Weber S., Ekindjian O.G., et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003, 48(12):3503-3508.
9. Allanore Y., Borderie D., Avouac J., Zerkak D., Meune C., Hachulla E., et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008, 58(1):284-291.
10. Mukerjee D., Yap L.B., Holmes A.M., Nair D., Ayrton P., Black C.M., et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003, 97(11):1230-1236.
11. Williams M.H., Handler C.E., Akram R., Smith C.J., Das C., Smee J., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27(12):1485-1494.
12. Choi H.J., Shin Y.K., Lee H.J., Kee J.Y., Shin D.W., Lee E.Y., et al. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 2008, 27(4):437-442.
13. Anon Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23(5):581-590.
14. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28(7):1573-1576.
15. Bredemeier M., Xavier R.M., Capobianco K.G., Restelli V.G., Rohde L.E., Pinotti A.F., et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004, 31(2):286-294.
16. Brennan P., Silman A., Black C., Bernstein R., Coppock J., Maddison P., et al. Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol 1992, 31(7):457-460.
17. Hachulla E., de Groote P., Gressin V., Sibilia J., Diot E., Carpentier P., et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009, 60(6):1831-1839.
18. Berger M., Haimowitz A., Van Tosh A., Berdoff R.L., Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985, 6(2):359-365.
19. Rakowski H., Appleton C., Chan K.L., Dumesnil J.G., Honos G., Jue J., et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996, 9(5):736-760.
20. Yap L.B., Ashrafian H., Mukerjee D., Coghlan J.G., Timms P.M. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004, 37(10):847-856.
21. Johnston N., Jernberg T., Lindahl B., Lindback J., Stridsberg M., Larsson A., et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004, 37(3):210-216.
22. Raymond I., Groenning B.A., Hildebrandt P.R., Nilsson J.C., Baumann M., Trawinski J., et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003, 89(7):745-751.
23. Ciurzynski M., Bienias P., Lichodziejewska B., Kurnicka K., Szewczyk A., Glinska-Wielochowska M., et al. Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 2008, 27(8):991-997.
24. Pedersen F., Raymond I., Kistorp C., Sandgaard N., Jacobsen P., Hildebrandt P. N-terminal pro-brain natriuretic peptide in arterial hypertension: a valuable prognostic marker of cardiovascular events. J Card Fail 2005, 11(5 Suppl):S70-S75.
25. Tschope C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005, 26(21):2277-2284.
26. Anon How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998, 19(7):990-1003.
27. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure?. Eur J Heart Fail 2004, 6(3):281-287.
28. Kahan A., Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006, 45(Suppl 4):iv14-iv17.
29. Sanchez-Roman J., Opitz C.F., Kowal-Bielecka O., Garcia-Hernandez F.J., Castillo-Palma M.J., Pittrow D. Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography. Rheumatology (Oxford) 2008, 47(Suppl 5):v33-v35.
30. Fisher M.R., Forfia P.R., Chamera E., Housten-Harris T., Champion H.C., Girgis R.E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(7):615-621.